According to a recent LinkedIn post from Truveta, peer-reviewed research using Truveta Data has been published in JACC: Advances examining use of GLP-1 therapies for cardiovascular patients. The post highlights that the U.S. Food and Drug Administration’s cardiovascular indication for semaglutide was followed by a rapid, short-term increase in therapy starts.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
However, the LinkedIn post notes that fewer than 1% of eligible patients with cardiovascular disease and overweight or obesity ultimately received semaglutide or tirzepatide. The post suggests that this gap between clinical evidence and real-world utilization underscores persistent barriers to access and adoption of these high-profile therapies.
For investors, the publication of research based on Truveta Data in a respected cardiovascular journal may indicate growing validation and visibility of the company’s data platform among academic and clinical stakeholders. Such validation could support Truveta’s positioning in the real-world evidence and healthcare analytics markets, which may be important for attracting life sciences and payer customers.
The findings also point to a meaningful disconnect between drug approvals and patient uptake, which may be relevant to pharmaceutical partners seeking to understand and close treatment gaps. If Truveta can consistently generate insights into utilization and access barriers for high-value therapies, it could enhance the commercial relevance of its datasets and analytics to industry clients and potentially support future revenue growth.